These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 18485993)

  • 1. Interleukin-12, interleukin-23, and psoriasis: ABT-874 in clinical trials.
    Wu JJ
    J Am Acad Dermatol; 2008 Jun; 58(6):1083; author reply 1083. PubMed ID: 18485993
    [No Abstract]   [Full Text] [Related]  

  • 2. ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases.
    Ding C; Xu J; Li J
    Curr Opin Investig Drugs; 2008 May; 9(5):515-22. PubMed ID: 18465662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis.
    Gandhi M; Alwawi E; Gordon KB
    Semin Cutan Med Surg; 2010 Mar; 29(1):48-52. PubMed ID: 20430307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Briakinumab.
    Lima XT; Abuabara K; Kimball AB; Lima HC
    Expert Opin Biol Ther; 2009 Aug; 9(8):1107-13. PubMed ID: 19569977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-12/23 monoclonal antibody for psoriasis.
    Okamoto H; Momohara S
    N Engl J Med; 2007 May; 356(19):2003; author reply 2003. PubMed ID: 17494940
    [No Abstract]   [Full Text] [Related]  

  • 6. Ustekinumab poised to enter the psoriasis market.
    Schmidt C
    Nat Biotechnol; 2008 Dec; 26(12):1317-8. PubMed ID: 19060851
    [No Abstract]   [Full Text] [Related]  

  • 7. Interleukin-12, interleukin-23, and psoriasis: current prospects.
    Torti DC; Feldman SR
    J Am Acad Dermatol; 2007 Dec; 57(6):1059-68. PubMed ID: 17706835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-12/IL-23 inhibitors: the advantages and disadvantages of this novel approach for the treatment of psoriasis.
    Bartlett BL; Moody MN; Tyring SK
    Skin Therapy Lett; 2008; 13(8):1-4. PubMed ID: 19145382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial.
    Kimball AB; Gordon KB; Langley RG; Menter A; Perdok RJ; Valdes J;
    J Am Acad Dermatol; 2011 Feb; 64(2):263-74. PubMed ID: 21145618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does p40-targeted therapy represent a significant evolution in the management of plaque psoriasis?
    Griffiths CE; Girolomoni G
    J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():2-8. PubMed ID: 22758911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecule of the month. Ustekinumab.
    Drug News Perspect; 2008 Apr; 21(3):182. PubMed ID: 18560616
    [No Abstract]   [Full Text] [Related]  

  • 12. New biologics for psoriasis and psoriatic arthritis.
    Rozenblit M; Lebwohl M
    Dermatol Ther; 2009; 22(1):56-60. PubMed ID: 19222517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ustekinumab for chronic plaque psoriasis.
    Bartlett BL; Tyring SK
    Lancet; 2008 May; 371(9625):1639-40. PubMed ID: 18486724
    [No Abstract]   [Full Text] [Related]  

  • 14. Go-ahead for first anti-IL-23 mAb to treat psoriasis.
    Nat Biotechnol; 2017 Sep; 35(9):806. PubMed ID: 28898221
    [No Abstract]   [Full Text] [Related]  

  • 15. Major cardiovascular events associated with anti-IL 12/23 agents: a tale of two meta-analyses.
    Dommasch ED; Troxel AB; Gelfand JM
    J Am Acad Dermatol; 2013 May; 68(5):863-5. PubMed ID: 23602173
    [No Abstract]   [Full Text] [Related]  

  • 16. New plaque psoriasis approval carries suicide warning.
    Mullard A
    Nat Rev Drug Discov; 2017 Mar; 16(3):155. PubMed ID: 28248935
    [No Abstract]   [Full Text] [Related]  

  • 17. Interleukin-23 inhibition for the treatment of psoriasis: the next frontier for high-efficacy biologic therapy.
    Strober B
    Br J Dermatol; 2015 Oct; 173(4):887-8. PubMed ID: 26511822
    [No Abstract]   [Full Text] [Related]  

  • 18. [Infliximab].
    Herrera E; Habicheyn S
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():7-13. PubMed ID: 19080986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Psoriasis. Inhibition of IL-17 signaling pathway by Secukinumab].
    Recker K
    Med Monatsschr Pharm; 2014 Jul; 37(7):267-8. PubMed ID: 25065169
    [No Abstract]   [Full Text] [Related]  

  • 20. [Simple and safe treatment offers new perspectives].
    Krankenpfl J; 2005; 43(1-3):56-7. PubMed ID: 15912845
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.